A 53-year-old industrialist from Gurugram recently visited the cardiology outpatient department at a leading Pune hospital with a familiar complaint: nine months of stubbornly elevated homocysteine levels despite increasing doses of folic acid. However, the document he carried was unusual: a sixty-page genetic report that, according to his consulting cardiologist, "changed the conversation entirely."
Genetic Insights Transform Treatment
The report revealed a homozygous variant in the MTHFR gene, indicating that the patient's body could not efficiently convert folic acid into methylfolate, the biologically active form needed to lower homocysteine. The patient was switched to methylfolate, and within three months, his homocysteine levels returned to normal for the first time in over a year.
This case is part of a growing trend across Indian cities and medical specialties, as pharmacogenomic testing moves from academic literature into mainstream clinical practice. Cardiologists, oncologists, and psychiatrists at hospitals such as AIIMS, Medanta, Fortis, and Apollo are increasingly ordering these tests for high-stakes treatment decisions, though it remains far from routine.
Clinical Actionability of Genetic Variants
"The most clinically actionable variant is CYP2C19," said a senior interventional cardiologist at a private Delhi tertiary hospital, who requested anonymity because his institution has not yet formally adopted pharmacogenomic testing. "It determines whether a patient can metabolize clopidogrel into its active form. A poor metabolizer is getting essentially no benefit from the drug we prescribed after their stent. They are at materially higher risk of a second event."
The concern is grounded in data. However, despite the evidence, pharmacogenomic testing is not part of routine clinical practice in India due to three main barriers: cost, awareness, and turnaround time. Standalone panels cost between ₹15,000 and ₹35,000, while whole-genome sequencing pushes the cost above ₹50,000. Most patients must pay out of pocket.
Innovative Solutions to Bridge Gaps
Mira One, a new integrated panel from Mumbai-based PreventiveHealth.ai in collaboration with GenePath Diagnostics, aims to address the awareness gap by bundling blood markers, a pharmacogenomic panel covering over 200 commonly prescribed medications, and whole-genome sequencing into a single investigation. The company describes it as a "once-in-a-lifetime" test, as genetic information does not change.
"We've been waiting for a test that doesn't make patients choose between blood work, drug response, and genetic predisposition," said Dr. Rashida Melinkeri, Clinical Program Director at PreventiveHealth.ai. "Three separate tests mean three separate visits, three separate interpretations. The clinical signal gets lost."
Market Growth and Accessibility
The Indian genomic testing market is now valued at USD 550 million and is growing at approximately 18% annually. Reliance's entry in December 2025 was widely seen as a signal that the category is moving from early-adopter to mainstream.
For patients, the practical question is when such a test adds clinical value. Clinicians point to four scenarios: individuals on chronic medication that is not working, those with a strong family history of cardiovascular disease or cancer, women with a family history of breast or ovarian cancer, and individuals planning long-term statin, antihypertensive, or antidepressant therapy.
"Used in the right patient, at the right time, this is some of the most valuable clinical information a physician can have," said the Delhi cardiologist. "Used as a longevity novelty, it is expensive entertainment. The difference is whether the patient and the physician sit down together and decide what to do with the result."
Increasingly, Indian patients are arriving at consultations with sixty-page reports already in hand. The question remains whether the medical establishment is ready to read them.
